Vericel (VCEL) Share-based Compensation (2010 - 2026)
Vericel (VCEL) reported Share-based Compensation of $11.3 million for Q1 2026, down 1.83% on a YoY basis from $11.5 million in Q1 2025, and up 269.89% sequentially from -$6.6 million in Q4 2025.
Vericel (VCEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Share-based Compensation data on file, last reported at $11.3 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 1.83% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at -$211000.0 (down 102.13% YoY), and the FY2024 full-year result was $3.3 million, down 89.83% from the prior year.
- Share-based Compensation advanced to $11.3 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $35.7 million in Q4 2022 to a low of -$25.3 million in Q4 2024.
- A 5-year average of $4.9 million and a median of $4.9 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 13362.3% in 2022 and jumped 29598.84% in 2024, its largest moves.
- Tracing VCEL's Share-based Compensation over 5 years: stood at $35.7 million in 2022, then dropped by 15.79% to $30.1 million in 2023, then slumped by 184.13% to -$25.3 million in 2024, then jumped by 73.71% to -$6.6 million in 2025, then jumped by 269.89% to $11.3 million in 2026.
- Business Quant data shows VCEL's Share-based Compensation at $11.3 million in Q1 2026, -$6.6 million in Q4 2025, and -$15.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 11.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.29 Mn |
| Mar 31, 2026 | 11.29 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -15.00 Mn |
| Sep 30, 2025 | -15.00 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Sep 30, 2024 | 25.54 Mn |
| Sep 30, 2024 | 25.54 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | 30.06 Mn |
| Dec 31, 2023 | 30.06 Mn |